Floatz logo

LAROPIPRANT

Polycystic Ovary Syndrome

Hull University Teaching Hospitals NHS TrustSmall moleculePhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Polycystic Ovary Syndrome cohort.

Asset / SponsorPhaseRating
Semaglutide
Methodist Health System
Phase 4BBB
Hcg
Eman Basuni Ebrahim Mowad
Phase 4BBB
Liraglutide
Peking University Third Hospital
Phase 4BBB
FOLLITROPIN BETA
Universitair Ziekenhuis Brussel
Phase 4BBB
Drospirenone
Ege University
Phase 4BBB

View all 50 →

Same molecule, other indications

LAROPIPRANT is also rated in:

hyperlipoproteinemiaDormant
B
Indicative ·
63 / 100
View asset →
coronary artery disorderDormant
B
Indicative ·
62 / 100
View asset →
cardiovascular disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →